Literature DB >> 17330841

The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma.

Christoph Renné1, Nora Hinsch, Klaus Willenbrock, Michael Fuchs, Wolfram Klapper, Andreas Engert, Ralf Küppers, Martin-Leo Hansmann, Andreas Bräuninger.   

Abstract

The Hodgkin-Reed/Sternberg (HRS) cells of classical Hodgkin's lymphoma (HL) aberrantly express up to 7 different receptor tyrosine kinases (RTK) with extensive heterogeneity regarding the number and combinations of expressed RTKs in individual cases and a more prominent coexpression in nodular-sclerosis (ns) than mixed-cellularity (mc) HL. To investigate whether RTK expression patterns are related to other pathogenetic mechanisms and clinical behaviour, we analysed a large collection of EBV(+) and EBV(-) cases of ns and mc subtype and cases with relapses for expression of the 7 RTKs. No specific relation of any RTK to a specific group of cases was observed. The analysis of average numbers of expressed RTKs per case as a measure for strength of overall RTK signalling revealed a relation with the histological subtype and the EBV-status. RTK coexpression was significantly higher in EBV(-) nsHL cases compared to both EBV(-) and EBV(+) mcHL cases. Among mcHL cases RTK coexpression was significantly higher in EBV(-) compared to EBV(+) cases. Coexpression of 3 and more RTKs was largely restricted to EBV(-) cases. The inverse correlation between strong RTK signalling and presence of EBV may indicate that RTK signalling can at least partially replace the role of EBV in HRS cell pathogenesis. For cases with aberrant coexpression of several RTKs inclusion of RTK inhibitors in therapy regimens may be a novel option.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330841     DOI: 10.1002/ijc.22511

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  [Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].

Authors:  C Renné; M L Hansmann; A Bräuninger
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

Review 2.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

3.  The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Authors:  Xiangmin Tong; Xuewu Zhang; Jian Fan; Yin Tong; Shuangshuang Li; Jie Jin; Hangping Yao
Journal:  Cancer Biol Ther       Date:  2013-01-29       Impact factor: 4.742

Review 4.  Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

Authors:  G Kapatai; P Murray
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

5.  Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.

Authors:  Zheng Liang; Arjan Diepstra; Chuanhui Xu; Gustaaf van Imhoff; Wouter Plattel; Anke Van Den Berg; Lydia Visser
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

Review 6.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

Review 7.  Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

Review 8.  The Microenvironment in Epstein-Barr Virus-Associated Malignancies.

Authors:  Geok Wee Tan; Lydia Visser; Lu Ping Tan; Anke van den Berg; Arjan Diepstra
Journal:  Pathogens       Date:  2018-04-13

9.  Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

Authors:  A Birgersdotter; K R N Baumforth; A Porwit; J Sjöberg; W Wei; M Björkholm; P G Murray; I Ernberg
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

Review 10.  Epstein-Barr virus-associated lymphomas.

Authors:  Claire Shannon-Lowe; Alan B Rickinson; Andrew I Bell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.